Understanding how the body makes and clears lipoproteins that raise heart disease risk
Official title: Biogenesis and Catabolism of Atherogenic Lipoproteins
Funded at New York University D/b/a NYU Long Island School of Medicine · NIH-11327652 · Data updated 2026-11-12
This grant studies how liver-produced apoB-containing lipoproteins are formed and broken down, with the goal of lowering factors that raise cardiovascular risk in people.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University D/b/a NYU Long Island School of Medicine NIH-funded |
| Lab location | 1 site (Mineola, United States) |
| Project start | May 1, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $2,418,566 |
| NIH project number | 5P01HL160470-04 |
| Project ID | NIH-11327652 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include adults with or at high risk for atherosclerotic cardiovascular disease who may benefit from therapies targeting apoB-containing lipoproteins.
✕Less likely to help
People without cardiovascular risk factors or those who would not be affected by changes in apoB-containing lipoproteins may not benefit.
What this research studies
Heart disease remains the leading cause of death, and this project looks at the biology of apoB-containing lipoproteins that drive atherosclerosis. Researchers will explore how these particles are created in the liver, how they are processed in the bloodstream, and how fat is stored and mobilized in fat tissue. They will use new rodent models and human data to connect basic mechanisms to potential treatments that could reduce circulating atherogenic lipoproteins and arterial plaque. The work aims to identify new targets to lower triglyceride-rich lipoproteins and prevent heart disease, with a translational focus toward human relevance.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that lower harmful lipoproteins and reduce cardiovascular risk for patients.
How similar studies have gone: Previous studies have linked changes in liver lipoprotein production to cardiovascular risk, and this project builds on that work with deeper mechanistic insights.
Where this research is happening
-
New York University D/b/a NYU Long Island School of Medicine
Mineola, United States Active
Researchers
- Principal investigator: Hussain, M Mahmood — New York University D/b/a NYU Long Island School of Medicine
- Study coordinator: Hussain, M Mahmood
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.